TransMedics, Inc.
200 Minuteman Road
Suite 302
Andover
Massachusetts
01810
United States
Tel: 978-552-0900
Fax: 978-685-9562
Website: http://www.transmedics.com/
Email: info@transmedics.com
79 articles about TransMedics, Inc.
-
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - February 16, 2024
2/16/2024
TransMedics Group, Inc. announced that on February 14, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 4,041 shares of its common stock and an aggregate of 2,627 restricted stock units to 9 employees, each as a material inducement for each employee's entry into employment with TransMedics.
-
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - January 16, 2024
1/16/2024
TransMedics Group, Inc. today announced that on January 12, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 24,535 shares.
-
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - December 12, 2023
12/12/2023
TransMedics Group, Inc. announced that on December 7, 2023, TransMedics granted non-qualified stock options to purchase an aggregate of 9,547 shares of its common stock and an aggregate of 6,175 restricted stock units to 11 employees, each as a material inducement for each employee's entry into employment with TransMedics.
-
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - November 03, 2023
11/3/2023
TransMedics Group, Inc. announced that on November 1, 2023, TransMedics granted non-qualified stock options to purchase an aggregate of 27,520 shares of its common stock and an aggregate of 17,670 restricted stock units to 10 employees, each as a material inducement for each employee's entry into employment with TransMedics.
-
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - October 10, 2023
10/10/2023
TransMedics Group, Inc. announced that on October 5, 2023, TransMedics granted non-qualified stock options to purchase an aggregate of 105,119 shares of its common stock and an aggregate of 67,288 restricted stock units to 21 employees, each as a material inducement for each employee's entry into employment with TransMedics.
-
TransMedics Acquires Warm Perfusion EVOSS™ and Cold Perfusion LifeCradle® Technologies from Bridge to Life
8/2/2023
TransMedics Group, Inc. announced that is has acquired from Bridge to Life Ltd., assets and intellectual property related to the Ex-Vivo Organ Support System and LifeCradle Heart Preservation Transport System technologies.
-
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 30, 2023
5/30/2023
TransMedics Group, Inc. announced that on May 24, 2023, TransMedics granted non-qualified stock options to purchase an aggregate of 87,472 shares of its common stock and an aggregate of 30,565 restricted stock units to 16 employees, each as a material inducement for each employee's entry into employment with TransMedics.
-
TransMedics Group, Inc. Announces Proposed Offering of $300 Million of Convertible Senior Notes Due 2028
5/8/2023
TransMedics Group, Inc. today announced that it intends to offer, subject to market and other conditions, $300 million aggregate principal amount of convertible senior notes.
-
TransMedics Releases Inaugural Environmental, Social & Governance (ESG) Report
5/1/2023
TransMedics Group, Inc., a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced that it has published its inaugural Environmental, Social & Governance report.
-
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - February 24, 2023
2/24/2023
TransMedics Group, Inc. announced that on February 20, 2023, TransMedics granted non-qualified stock options to purchase an aggregate of 72,774 shares of its common stock to seven employees and an aggregate of 17,092 restricted stock units to three employees, each as a material inducement for each employee's entry into employment with TransMedics.
-
TransMedics to Present at Upcoming March 2023 Investor Conferences
2/21/2023
TransMedics Group, Inc., a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced the company will be participating in two upcoming investor conferences.
-
TransMedics to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023
2/8/2023
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2022 after market close on Wednesday, February 22, 2023.
-
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - November 07, 2022
11/7/2022
TransMedics Group, Inc., a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced that on November 2, 2022, TransMedics granted non-qualified stock options to purchase an aggregate of 138,400 shares of its common stock to six employees as a material inducement for each employee's entry into employment with TransMedics.
-
TransMedics Reports Third Quarter 2022 Financial Results
11/3/2022
TransMedics Group, Inc., a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, reported financial results for the quarter ended September 30, 2022.
-
TransMedics to Report Third Quarter 2022 Financial Results on November 3, 2022
10/20/2022
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter of 2022 after market close on Thursday, November 3, 2022.
-
TransMedics Announces Proposed Public Offering of Common Stock - Aug 03, 2022
8/3/2022
TransMedics Group, Inc., a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced the commencement of a proposed public offering of $100 million of its shares of common stock.
-
TransMedics to Present at the Canaccord Genuity 42nd Annual Growth Conference
7/26/2022
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), today announced that members of the management team will present at the upcoming Canaccord Genuity 42nd Annual Growth Conference at the InterContinental Boston Hotel.
-
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - June 03, 2022
6/3/2022
TransMedics Group, Inc. announced that on June 1, 2022, TransMedics granted non-qualified stock options to purchase an aggregate of 35,000 shares of its common stock to three employees as a material inducement for each employee's entry into employment with TransMedics.
-
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Feb 25, 2022
2/25/2022
TransMedics Group, Inc., a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced that on February 22, 2022, TransMedics granted non-qualified stock options to purchase an aggregate of 158,500 shares of its common stock to eight employees as a material inducement for each employee's entry into employment with TransMedics.
-
TransMedics Reports Fourth Quarter and Full Year 2021 Financial Results
2/23/2022
TransMedics Group, Inc., a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, reported financial results for the quarter and year ended December 31, 2021.